Peptides of Tetraspanin Oncoprotein CD151 Trigger Active Immunity Against Primary Tumor and Experimental Lung Metastasis

2019 ◽  
Author(s):  
Wanzun Lin ◽  
Jun Liu ◽  
Juhui Chen ◽  
Jiancheng Li ◽  
Sufang Qiu ◽  
...  
Keyword(s):  
Lung Metastasis ◽  
Primary Tumor ◽  
Active Immunity

scholarly journals Resection of lung metastasis of gastrointestinal stromal tumor after resection of primary tumor

2016 ◽  
Vol 30 (1) ◽  
pp. 19-24
Author(s):  
Hironori Oyamatsu ◽  
Norihisa Ohata ◽  
Kunio Narita
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Lung Metastasis ◽  
Primary Tumor ◽  
Stromal Tumor

scholarly journals Lung Metastasis Mimicking Fingertip Infection

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Salih Soylemez ◽  
Murat Demiroglu ◽  
Mehmet Ali Yayla ◽  
Korhan Ozkan ◽  
Bugra Alpan ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Life Expectancy ◽  
Medical History ◽  
Lung Metastasis ◽  
Primary Tumor ◽  
Poor Prognosis ◽  
Past Medical History

Metastasis fingers (acral metastasis) are finding a poor prognosis. Past medical history should be questioned and metastasis from primary tumor should be kept in mind in patients with pain, swelling, and hyperemia in fingers. Successful surgical treatment on acral metastasis does not extend the life expectancy; however, it reduces the patient’s pain during his terminal period, saves the functions of the limb, and increases life comfort.

Lung metastasis as predictor for prognosis in metastatic colorectal cancer with mutated KRAS.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 636-636
Author(s):  
Ben Boursi ◽  
Einat shacham-Shmueli ◽  
Yaacov Richard Lawrence ◽  
Yu-Xiao Yang ◽  
Kim Anna Reiss ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Metastatic Colorectal Cancer ◽  
Lung Metastasis ◽  
Primary Tumor ◽  
Clinical Decision Making ◽  
Secondary Analysis ◽  
Tumor Location ◽  
Single Site ◽  
Primary Tumor Location

636 Background: Previous studies have shown that prognosis in metastatic colorectal cancer (mCRC) may vary according to sites of metastasis. We evaluated prognosis in individuals with single site metastasis, according to several clinical and genetic variables. Methods: Using the National Cancer Database we identified 58,044 mCRC patients with a synchronous single site of metastasis. We first examined the effect of metastasis site on prognosis. In a secondary analysis, among individuals who had not undergone surgery or received radiotherapy, we examined the prognostic value of chemotherapy intensity, KRAS status, primary tumor location and CEA levels. Results: Individuals with lung metastasis had the best prognosis (HR = 0.80, 0.77-0.83), followed by those with liver metastasis (HR = 1.11, 1.07-1.15), while those with bone or brain metastasis had the worse prognosis. In a subgroup analysis, we assessed prognosis among individuals who received multi-agent chemotherapy and had not undergone surgery or received radiotherapy. Individuals with lung metastasis and mutant KRAS had better prognosis compared with those with liver metastasis, (HR = 0.69, 0.54-0.88), regardless of primary tumor location or CEA levels. Conclusions: Single site metastasis to the lungs is associated with better prognosis in mCRC, specifically among KRAS mutant tumors. This survival advantage should be taken into consideration in clinical decision-making.

Effect of general anesthetics on the tumor micro-environment in mouse models of breast cancers of spontaneous metastasis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15503-e15503
Author(s):  
Jun Lin ◽  
Ru Li ◽  
Yujie Huang
Keyword(s):  
Breast Cancer ◽  
Mouse Models ◽  
Lung Metastasis ◽  
Primary Tumor ◽  
Cancer Metastasis ◽  
Metastatic Breast ◽  
Health Concern ◽  
Breast Cancers ◽  
General Anesthetics ◽  
Primary Tumors

e15503 Background: Metastatic breast cancer is a pressing health concern worldwide. Various treatments have been developed but no significant long-term changes in overall survival are observed. Therefore, there is a demand to improve current therapies to treat this disease. Surgical resection of the primary tumors is essential in the treatment. However, accumulating evidence alludes to a role for volatile anesthetics which are used during the surgery in metastatic tumor development, but the mechanism remains largely unknown. We have shown anesthetics exert different effects on lung metastasis in mouse models of breast cancers. This study analyses the effect of general anesthetics in lung microenvironment associated with the increased metastases. Methods: Balb/c mice and NOD-SCID mice were orthotopically implanted with 4T1 cells and MDA-MB-231 cells respectively, in the mammary fat pad to generate primary tumors. Mice were subjected to the tested anesthetic during implantation and/or before and after surgery. Surgical dissection of primary tumor was performed under anesthesia with sevoflurane or an intravenous anesthetic propofol. Survival curve was constructed and analysed. Mice were euthanized to harvest tissues for histology and cell analysis. Results: As we previously reported, surgical dissection of primary tumor in mice under anesthesia with sevoflurane led to significantly more lung metastasis than with propofol in both syngeneic murine 4T1 and xenograft human MDA-MB-231 breast cancer models. Sevoflurane was associated with increased IL6(Li, Huang, & Lin, 2020). Here we show that anesthesia with sevoflurane resulted in changes of stroma composition in the lung, which was reversed by IL6 pathway interruption. Conclusions: Those results contribute to our understanding of effects of sevoflurane on cancer metastasis and suggest a potential therapeutic approach to overcome the risk of general anesthesia. Li, R., Huang, Y., & Lin, J. (2020). Distinct effects of general anesthetics on lung metastasis mediated by IL-6/JAK/STAT3 pathway in mouse models. Nat Commun, 11, 642.

scholarly journals Host deficiency in ephrin-A1 inhibits breast cancer metastasis

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 217 ◽  
Author(s):  
Eileen Shiuan ◽  
Ashwin Inala ◽  
Shan Wang ◽  
Wenqiang Song ◽  
Victoria Youngblood ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Cancer Cell ◽  
Lung Metastasis ◽  
Primary Tumor ◽  
Tumor Recurrence ◽  
Cancer Metastasis ◽  
Primary Tumor Growth ◽  
Primary Tumors ◽  
4T1 Cells

Background: The conventional dogma of treating cancer by focusing on the elimination of tumor cells has been recently refined to include consideration of the tumor microenvironment, which includes host stromal cells. Ephrin-A1, a cell surface protein involved in adhesion and migration, has been shown to be tumor suppressive in the context of the cancer cell. However, its role in the host has not been fully investigated. Here, we examine how ephrin-A1 host deficiency affects cancer growth and metastasis in a murine model of breast cancer. Methods: 4T1 cells were orthotopically implanted into the mammary fat pads or injected into the tail veins of ephrin-A1 wild-type (Efna1+/+), heterozygous (Efna1+/-), or knockout (Efna1-/-) mice. Tumor growth, lung metastasis, and tumor recurrence after surgical resection were measured. Flow cytometry and immunohistochemistry (IHC) were used to analyze various cell populations in primary tumors and tumor-bearing lungs. Results: While primary tumor growth did not differ between Efna1+/+, Efna1+/-, and Efna1-/- mice, lung metastasis and primary tumor recurrence were significantly decreased in knockout mice. Efna1-/- mice had reduced lung colonization of 4T1 cells compared to Efna1+/+ littermate controls as early as 24 hours after tail vein injection. Furthermore, established lung lesions in Efna1-/- mice had reduced proliferation compared to those in Efna1+/+ controls. Conclusions: Our studies demonstrate that host deficiency of ephrin-A1 does not impact primary tumor growth but does affect metastasis by providing a less favorable metastatic niche for cancer cell colonization and growth. Elucidating the mechanisms by which host ephrin-A1 impacts cancer relapse and metastasis may shed new light on novel therapeutic strategies.

scholarly journals Immunoregulatory Monocyte Subset Promotes Metastasis Associated With Therapeutic Intervention for Primary Tumor

2021 ◽  
Vol 12 ◽  
Author(s):  
Takumi Shibuya ◽  
Asami Kamiyama ◽  
Hirotaka Sawada ◽  
Kenta Kikuchi ◽  
Mayu Maruyama ◽  
...  
Keyword(s):  
Lung Metastasis ◽  
Therapeutic Intervention ◽  
Primary Tumor ◽  
Tissue Repair ◽  
Target Cells ◽  
Monocyte Subset ◽  
Local Inflammation ◽  
Cxcr4 Antagonist ◽  
Metastatic Recurrence ◽  
Metalloproteinase 9

Systemic and local inflammation associated with therapeutic intervention of primary tumor occasionally promotes metastatic recurrence in mouse and human. However, it remains unclear what types of immune cells are involved in this process. Here, we found that the tissue-repair-promoting Ym1+Ly6Chi monocyte subset expanded as a result of systemic and local inflammation induced by intravenous injection of lipopolysaccharide or resection of primary tumor and promoted lung metastasis originating from circulating tumor cells (CTCs). Deletion of this subset suppressed metastasis induced by the inflammation. Furthermore, transfer of Ym1+Ly6Chi monocytes into naïve mice promoted lung metastasis in the mice. Ym1+Ly6Chi monocytes highly expressed matrix metalloproteinase-9 (MMP-9) and CXCR4. MMP-9 inhibitor and CXCR4 antagonist decreased Ym1+Ly6Chi-monocyte-promoted lung metastasis. These findings indicate that Ym1+Ly6Chi monocytes are therapeutic target cells for metastasis originating from CTCs associated with systemic and local inflammation. In addition, these findings provide a novel predictive cellular biomarker for metastatic recurrence after intervention for primary tumor.

scholarly journals A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yu Lu ◽  
Di Zhu ◽  
Lin Gui ◽  
Yuanming Li ◽  
Wenjing Wang ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Lung Metastasis ◽  
Dna Cleavage ◽  
Primary Tumor ◽  
Cell Cycle Progression ◽  
Chloride Ions ◽  
Lewis Lung Cancer ◽  
Dual Targeting

Abstract Background Many studies have found that ruthenium complexes possess unique biochemical characteristics and inhibit tumor growth or metastasis. Results Here, we report the novel dual-targeting ruthenium candidate 2b, which has both antitumor and antimetastatic properties and targets tumor sites through the enhanced permeability and retention (EPR) effect and transferrin/transferrin receptor (TF/TFR) interaction. The candidate 2b is composed of ruthenium-complexed carboline acid and four chloride ions. In vitro, 2b triggered DNA cleavage and thus blocked cell cycle progression and induced apoptosis via the PARP/ATM pathway. In vivo,2b inhibited not only Lewis lung cancer (LLC) tumor growth but also lung metastasis. We detected apoptosis and decreased CD31 expression in tumor tissues, and ruthenium accumulated in the primary tumor tissue of C57BL/6 mice implanted with LLC cells. Conclusions Thus, we conclude that 2b targets tumors, inhibits tumor growth and prevents lung metastasis.

Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model

2013 ◽  
Author(s):  
Bryan D. Smith ◽  
Molly M. Hood ◽  
Michael D. Kaufman ◽  
Mark Berger ◽  
Daniel L. Flynn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Lung Metastasis ◽  
Small Molecule ◽  
Primary Tumor ◽  
Kinase Inhibitor ◽  
Primary Tumor Growth ◽  
Cancer Model ◽  
Breast Cancer Model

scholarly journals P2.04-027 Targeting Adenosine A2B Receptor for Modulation of Tumor Microenvironment, Primary Tumor Growth, and Lung Metastasis

2017 ◽  
Vol 12 (1) ◽  
pp. S1013
Author(s):  
Jason Evans ◽  
Andrey Bobko ◽  
Stephanie Lewis ◽  
Charles Martin ◽  
Mohammed Rahman ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Tumor Growth ◽  
Lung Metastasis ◽  
Primary Tumor ◽  
Primary Tumor Growth ◽  
Adenosine A2b Receptor ◽  
A2b Receptor ◽  
Adenosine A2b

scholarly journals Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1

2015 ◽  
Vol 112 (52) ◽  
pp. 16000-16005 ◽  
Author(s):  
Tina El Rayes ◽  
Raúl Catena ◽  
Sharrell Lee ◽  
Marcin Stawowczyk ◽  
Natasha Joshi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Tumor Progression ◽  
Lung Metastasis ◽  
Therapeutic Target ◽  
Primary Tumor ◽  
Lung Inflammation ◽  
Cathepsin G ◽  
Genetic Ablation ◽  
Thrombospondin 1 ◽  
Tumor Outgrowth

Inflammation is inextricably associated with primary tumor progression. However, the contribution of inflammation to tumor outgrowth in metastatic organs has remained underexplored. Here, we show that extrinsic inflammation in the lungs leads to the recruitment of bone marrow-derived neutrophils, which degranulate azurophilic granules to release the Ser proteases, elastase and cathepsin G, resulting in the proteolytic destruction of the antitumorigenic factor thrombospondin-1 (Tsp-1). Genetic ablation of these neutrophil proteases protected Tsp-1 from degradation and suppressed lung metastasis. These results provide mechanistic insights into the contribution of inflammatory neutrophils to metastasis and highlight the unique neutrophil protease–Tsp-1 axis as a potential antimetastatic therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document